Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Summary of Significant Accounting Policies

Schedule Of Cash And Cash Equivalents And Short Term Investments

Short-term investments at December 31, 2019 consisted of the following (in thousands):

							Estimated
			Amortization/		Unrealized		Fair
	Cost		Accretion		Gains/(Losses)		Value
Corporate debt securities	$	9,284	$	5	$	(4)	$	9,285

Disaggregation of Revenue

The following table presents revenue disaggregated by our portfolio of products (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
OviTex	$	4,526	$	3,402	$	10,707	$	9,920
OviTex PRS		787		571		1,839		662
Total revenue	$	5,313	$	3,973	$	12,546	$	10,582

Schedule of fair value of assets and liabilities measured on recurring basis

The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	Fair value measurement at reporting date using
	Quoted prices in
	active markets		Significant other		Significant
	for identical		observable		unobservable
	assets		inputs		inputs
	(Level 1)		(Level 2)		(Level 3)
September 30, 2020:
Assets:
Cash equivalents – money market fund	$	78,887	$	—	$	—
December 31, 2019:
Assets:
Cash equivalents – money market fund	$	34,918	$	—	$	—
Cash equivalents – corporate debt securities	$	—	$	8,850	$	—
Cash equivalents – government agency securities	$	—	$	1,000	$	—
Short-term investments – corporate debt securities	$	—	$	9,285	$	—

Schedule of warrant liability

At September 30, 2019, preferred stock warrants were outstanding and were a level 3 measurement. A rollforward of the warrant liability is as follows (in thousands):

January 1, 2019	$	1,640
Change in fair value of warrants		4
September 30, 2019	$	1,644

Schedule of dilutive securities excluded

	Three and nine months ended September 30,
	2020	2019
Series A redeemable convertible preferred stock	—	911,336
Series B redeemable convertible preferred stock	—	3,060,302
Stock options (including shares subject to repurchase)	1,495,642	552,605
Series B redeemable convertible preferred stock warrants	—	88,556
Common stock warrants	88,556	—
Total	1,584,198	4,612,799